Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity
- 1 November 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (9) , 3293-3299
- https://doi.org/10.1182/blood-2004-11-4526
Abstract
We have recently demonstrated that the proteasome inhibitor, bortezomib, administered immediately following murine allogeneic bone marrow transplantation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of graft-versus-tumor effects. We now assessed the effects of delayed bortezomib administration (5 or more days after BMT) on GVHD. Recipient C57BL/6 (H2b) mice were lethally irradiated and given transplants of bone marrow cells and splenocytes from major histocompatibility complex (MHC)–disparate BALB/c (H2d) donors. In marked contrast to the effects of bortezomib on GVHD prevention when administered immediately after BMT, delayed bortezomib administration resulted in significant acceleration of GVHD-dependent morbidity. No toxicity was observed following delayed bortezomib administration in models where donor T cells were not coadministered, indicating that these deleterious effects were critically dependent on GVHD induction. The increase in GVHD susceptibility even occurred when late administration of bortezomib was preceded by early administration. Pathologic assessment revealed that significant increases in gastrointestinal lesions occurred following delayed bortezomib administration during GVHD. This pathology correlated with significant increases of type 1 tumor necrosis factor α (TNF-α) receptor transcription in gastrointestinal cells and with significant increases of TNF-α, interleukin 1β (IL-1β), and IL-6 levels in the serum. These results indicate that the differential effects of proteasome inhibition with bortezomib on GVHD are critically dependent on the timing of bortezomib administration.Keywords
This publication has 34 references indexed in Scilit:
- Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-κBJournal of Biological Chemistry, 2004
- Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK ReceptorsClinical Cancer Research, 2004
- The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIPBlood, 2003
- NF-κB regulation in the immune systemNature Reviews Immunology, 2002
- The Susceptibility to Fas-Induced Apoptosis in Normal Enterocytes Is Regulated on the Level of cIAP1 and 2Biochemical and Biophysical Research Communications, 2002
- INHIBITION OF NF-κB BY IκB PREVENTS CYTOKINE-INDUCED NO PRODUCTION AND PROMOTES ENTEROCYTE APOPTOSIS IN VITROShock, 2000
- NF-κB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell typeCell Death & Differentiation, 1999
- Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.Journal of Clinical Investigation, 1998
- An Essential Role for NF-κB in Preventing TNF-α-Induced Cell DeathScience, 1996
- In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.The Journal of Experimental Medicine, 1990